Results of Observational Study and Integration of Epinastine 0,05% in Treatment Algorythms of Patients with Seasonal Allergic Conjunctivitis

Author:

Maychuk D. Yu.1ORCID,Drozdova E. A.2,Tarkhanova A. A.1ORCID,Zinych E. E.1ORCID

Affiliation:

1. The S. Fyodorov Eye Microsurgery Federal State Institution

2. South Ural State Medical University

Abstract

Objective. To assess tolerability and the time of onset of clinical effect of dual­-action antihistamine agents — Epinepta® (epinastine 0.05 %) and olopatadine 0.1 % in patients with seasonal allergic conjunctivitis (SAC).Subjects and methods. This was a prospective multicenter observational study. One hundred fifty patients with SAC (n = 150) were included into the study and divided into two groups (n = 75) in each. Patients in group 1 received epinastine 0.05 %, while patients into group 2 received olopatadine 0.1 %. Evaluation of clinical symptoms severity was performed using itching scale, hyperemia Efrone scale, eyelid swelling scale, lacrimation P. Munk scale, Shirmer test and Norn probe. Patients and healthcare providers satisfaction rate was assessed by Likert scale, patients self-­control diary that helped to assess dry eye severity symptoms. Treatment period lasted 14 days.Results. Seasonal allergic conjunctivitis treatment with epinastine 0.05 % or olopatadine 0.1 % was equally effective. However epinastine 0.05 % was causing dry eye symptoms in lesser degree than olopatadine 0.1 %. These results refer to all parameters assessed by patients’ self­-control diary — itching, discomfort, burning, eye blockage feeling.Conclusion. The study evaluated epinastine 0.05 % advantages compared to olopatadine 0.1 % in tear film preservation and causing less pronounced symptoms of dry eye in patients with acute seasonal allergic conjunctivitis. Monotherapy of seasonal allergic conjunctivitis with epinastine 0.05 % demonstrated high efficacy and lead to SAC clinical manifestations regress. Epinastine 0.05 % is recommended as a first line treatment of SAC. 

Publisher

PE Polunina Elizareta Gennadievna

Reference18 articles.

1. Maichuk YuF. Seasonal pollen‑induced allergic conjunctivitis as the most common form of eye allergy. Part 1: epidemiology, aetiology, pathophysiology, clinical symptoms and diagnostics. Russian Ophthalmological Journal. 2010;3(1):37–41 (In Russ.).

2. Maichuk YuF. Allergic eye diseases. Moscow: Medicine, 1983. 224 p. (In Russ.).

3. Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol. 2011 Feb;106(2 Suppl):S2–5. doi: 10.1016/j.anai.2010.08.005.

4. Villegas BV, Benitez‑Del‑Castillo JM. Current Knowledge in Allergic Conjunctivitis. Turk J Ophthalmol. 2021 Feb 25;51(1):45–54. doi: 10.4274/tjo.galenos.2020.11456.

5. Maychuk DYu. Modern opportunities of therapeutic treatment of allergic conjunctivitis. A review. Ophthalmology in Russia. 2014;11(2):19–26. (In Russ.). doi: 10.18008/1816‑5095‑2014‑2‑19‑26.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3